We’re often reminded of why we put an effort in supporting people facing cancer – whether it comes through a patient story or through an organization’s investment in our work. This week, we humbly received another reminder: on Friday, May 22, the International Chronic Myeloid Leukemia (CML) Foundation awarded our CEO Pat Garcia-Gonzalez with the inaugural ERSAP (Emerging Region Support and Partnership) Prize. The iCMLf Directors and Scientific Advisors selected Pat because of her continued commitment, and The Max Foundation’s aim, to help people face cancer with dignity and hope.
Tim Hughes, iCMLf Chair, stated, “Pat strongly believes that people living with CML have the right to access the best possible treatment and support, wherever they live. This is why she has been so determined to make new drugs for CML fully available to patients in emerging economic regions through access programs, education and global advocacy efforts.”
“I am honored to receive the first ever ERSAP Prize and thank our partners at the International CML Foundation for their recognition.” Pat stated. “I take this award as an opportunity to reflect on how providing access to life-saving treatments to people around the world makes our global community stronger and a more just place to live. There are still so many people around the world who deserve advocacy and support and we carry out our work on their behalf. This award reignites our passion for finding innovative solutions to help people face cancer with dignity and hope.”
You can read further details about why Pat was selected for the ERSAP Prize on the iCMLf announcement.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
At The Max Foundation we are all about patients; deeply, profoundly, committed to patients and by extension their families and communities. To continue to foster this commitment, once a year we honor a team member who has exemplified our values and beliefs with the Excellence in Patient Advocacy Award. We are proud to announce the….
This year, we’re celebrating 25 years of partnership with Novartis. Together, we’ve provided access to treatment for more than 100,000 people living with cancer in low- and middle-income countries. Below, eight patients from four locations where we operate share their stories. They talk about how they were diagnosed, the impact of having treatment, and what’s….
In 2001, The Max Foundation partnered with the pharmaceutical corporation Novartis to develop an international treatment access program for people living with chronic myeloid leukemia (CML). Since then, we’ve helped thousands of patients in low- and middle-income countries access life-extending diagnostics, medication, and support services. A lot has changed over the years, but our focus….
